PharmGKB pathway diagrams
PharmGKB pathway diagrams. (A) The antiestrogen pathway: PK describes the hepatic metabolism of the drug tamoxifen (purple rectangle) to several primary and secondary metabolites (purple-yellow rectangles) by the cytochrome P450 (CYP) enzymes. Like tamoxifen, some of these metabolites exhibit antiestrogenic effects, indicated by arrows to the breast cancer cell. Along the arrows, the genes (blue ovals) are displayed, which code for the involved CYP isoforms. In the transformation to the potent antiestrogenic metabolite, 4-hydroxy-tamoxifen, CYP2D6 plays a significant role, indicated by the star. A summary explaining the different shapes and colors used in the graphic is available through the “legend” link. (B) The antiestrogen pathway: PD displays genes (blue ovals) involved in the synthesis of estrogens (green ovals) and the effect of estrogens on downstream signals by binding to estrogen receptors. Aromatase inhibitors (purple rectangle) are a group of drugs that reduce the amount of estrogens by blocking their transformation from androgens, whereas selective estrogen-receptor modulators (SERM) decrease the cellular effects of estrogens by binding to estrogen receptors in breast cells. The two drug groups are major pharmacological strategies in breast cancer therapy of estrogen receptor and/or progesterone receptor–positive breast tumors.
Publication
PharmGKB: UNDERSTANDING THE EFFECTS OF INDIVIDUAL GENETIC VARIANTS. () Katrin Sangkuhl, et al. Drug Metab Rev. ;40(4):539-551. Figure: F3.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | (HSD17B1) | HSD17B1 | ncbigene_symbol | HSD17B1 | 3292 |
| Homo sapiens | Primates | CYP2B6 | CYP2B6 | ncbigene_symbol | CYP2B6 | 1555 |
| Homo sapiens | Primates | CYP2C19 | CYP2C19 | ncbigene_symbol | CYP2C19 | 1557 |
| Homo sapiens | Primates | CYP3A4 | CYP3A4 | ncbigene_symbol | CYP3A4 | 1576 |
| Homo sapiens | Primates | CYP2C9 | CYP2C9 | ncbigene_symbol | CYP2C9 | 1559 |
| Homo sapiens | Primates | CYP19A1 | CYP19A1 | ncbigene_symbol | CYP19A1 | 1588 |
| Homo sapiens | Primates | CYP2D6 | CYP2D6 | ncbigene_symbol | CYP2D6 | 1565 |
| Homo sapiens | Primates | CYP2D6 | CYP2D6 | ncbigene_synonym | CYP2D7 | 1564 |
| Homo sapiens | Primates | ESR2 | ESR2 | ncbigene_symbol | ESR2 | 2100 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| 4-OH tamoxifen | NA | mesh:C016601 | ||
| Endoxifen | 4-Hydroxy-N-desmethyltamoxifen | mesh:C055492 | 4-hydroxy-N-desmethyltamoxifen | chebi:80555 |
| Androstenedione | Androstenedione | mesh:D000735 | androst-4-ene-3,17-dione | chebi:16422 |
| Estradiol | Estradiol | mesh:D004958 | 17beta-estradiol | chebi:16469 |
| Estrone | Estrone | mesh:D004970 | estrone | chebi:17263 |
| Tamoxifen | Tamoxifen | mesh:D013629 | tamoxifen | chebi:41774 |
| tamoxifen | Tamoxifen | mesh:D013629 | tamoxifen | chebi:41774 |
| Testosterone | Testosterone | mesh:D013739 | testosterone | chebi:17347 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|